Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms

被引：13
|
作者：
Barnet, Megan B. [1 ,2 ,3 ]
Cooper, Wendy A. [3 ,4 ,5 ]
Boyer, Michael J. [3 ,6 ]
Kao, Steven [3 ,6 ]
机构：
[1] Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia
[2] Univ New South Wales, Grad Res Sch, Sydney, NSW 2052, Australia
[3] Univ Sydney, Sydney Med Sch, Camperdown, NSW 2006, Australia
[4] Royal Prince Alfred Hosp, Camperdown, NSW 2006, Australia
[5] Western Sydney Univ, Sch Med, Penrith, NSW 2751, Australia
[6] Chris OBrien Lifehouse, Camperdown, NSW 2006, Australia
来源：
JOURNAL OF CLINICAL MEDICINE | 2018年 / 7卷 / 06期
关键词：
non-small cell lung cancer; immunotherapy; checkpoint inhibitors; MAINTENANCE THERAPY; OPEN-LABEL; NIVOLUMAB; DOCETAXEL; CHEMOTHERAPY; MULTICENTER; IPILIMUMAB; ANTIBODY; NECROSIS; PLACEBO;
D O I：
10.3390/jcm7060151
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Immune checkpoint inhibitors have shown efficacy in the treatment of non-small cell lung cancer (NSCLC) in the adjuvant, first- and subsequent-line settings. In metastatic disease, they provide hope of durable response where best-case scenario has long been inadequate. This progress has highlighted the immunogenic nature of NSCLC and invigorated research into immunotherapy in the field. In this review we consider the foundations of immunotherapy in NSCLC, canvass the current research and summarise the evidence guiding clinical practice.
引用
收藏
页数：14
相关论文
共 50 条
  • [41] Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer
    Pennell, Nathan A.
    SEMINARS IN ONCOLOGY, 2015, 42 (05) : S3 - S10
  • [42] Personalized immunotherapy for advanced non-small cell lung cancer
    Herbst, Roy S.
    ANNALS OF ONCOLOGY, 2015, 26 : 16 - 16
  • [43] Immunotherapy as a targeted therapy in non-small cell lung cancer
    Rocco, Danilo
    Della Gravara, Luigi
    Avellino, Aniello
    Montesarchio, Vincenzo
    Battiloro, Ciro
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S70 - S75
  • [44] The State of the Art in Non-Small Cell Lung Cancer Immunotherapy
    Seetharamu, Nagashree
    SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2014, 26 (01) : 26 - 35
  • [45] Neoadjuvant immunotherapy for resectable non-small cell lung cancer
    Xie, Hui
    Shi, Xuejun
    Wang, Guangshun
    AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 11 (06): : 2521 - 2536
  • [46] New strategies in immunotherapy for non-small cell lung cancer
    Carrizosa, Daniel R.
    Gold, Kathryn A.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2015, 4 (05) : 553 - 559
  • [47] THE SOCIAL VALUE OF IMMUNOTHERAPY IN NON-SMALL CELL LUNG CANCER
    Sullivan, J.
    Ward, Sexton A.
    Korytowsky, B.
    Peneva, D.
    Benner, J.
    Lakdawalla, D. N.
    Bolinder, B.
    Figlin, R. A.
    Jena, A. B.
    VALUE IN HEALTH, 2016, 19 (03) : A167 - A167
  • [48] Neoadjuvant Immunotherapy for Patients with non-small cell Lung Cancer
    Luecke, E.
    Ganzert, C.
    Waesche, A.
    Walles, T.
    Schreiber, J.
    PNEUMOLOGIE, 2020, 74 : S74 - S75
  • [49] Immunotherapy through the Lens of Non-Small Cell Lung Cancer
    Stanley, Robyn
    Flanagan, Saoirse
    O'Reilly, David
    Kearney, Ella
    Naidoo, Jarushka
    Dowling, Catriona M.
    CANCERS, 2023, 15 (11)
  • [50] Biomarkers for immunotherapy resistance in non-small cell lung cancer
    Rother, Catriona
    John, Tom
    Wong, Annie
    FRONTIERS IN ONCOLOGY, 2024, 14
12345